We are thrilled to announce significant progress in validating our diagnostic workflow, iSEP-SEQ, which has been tested in over 400 plasma samples and validated in 20 patients across two countries- Malawi and Germany. This milestone has been achieved through our collaborations with leading institutions, including the Malawi-Liverpool-Wellcome Clinical Research Programme, Liverpool School of Tropical Medicine, and Universitätsmedizin Mainz.
iSEP-SEQ demonstrated its capability to detect sepsis-causing pathogens quickly and effectively, even in cases where standard blood culture fell short. By identifying pathogens directly from blood samples in under six hours, iSEP-SEQ addresses a critical need for faster, more accurate diagnostics in sepsis care. Moreover, it's applications are not limited to bacterial infections, and can be adapted to a wide range of pathogens including bacteria, fungi, virus and parasites.
This validation highlights the global potential of iSEP-SEQ in improving clinical outcomes, reducing antimicrobial resistance (AMR), and supporting healthcare providers in delivering timely, targeted treatment. We are proud to work alongside esteemed collaborators to drive innovation in infectious disease diagnostics.
Stay connected for updates as we continue advancing our workflow!